Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis.
IAP
NF-κB
Pancreatic cancer
Small-molecule inhibitor
UbcH5c
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
10 03 2022
10 03 2022
Historique:
received:
12
01
2022
accepted:
08
02
2022
entrez:
11
3
2022
pubmed:
12
3
2022
medline:
23
4
2022
Statut:
epublish
Résumé
Pancreatic cancer is one of the most lethal cancers worldwide. The IAPs function as E3 ubiquitin ligases and contribute to pancreatic cancer initiation, progression, and metastasis. Although IAP-targeted therapies have been developed and shown anticancer efficacy in preclinical settings, none of them has been approved yet. Transcriptome data from public datasets were used to analyze the correlation of IAPs and E2s, and the biological function of E2 UbcH5c in pancreatic cancer. A structure-based virtual screen was used to identify UbcH5c inhibitor, and surface plasmon resonance analysis and cellular thermal shift assays were employed to evaluate the binding affinity. The anticancer activities were demonstrated through in vitro and in vivo assays, while the related mechanisms were explored through transcriptomic and proteomic analyses and confirmed by western blot, immunofluorescence, and qRT-PCR. UbcH5c is positively correlated with the expression of IAPs in pancreatic cancer. We further found that UbcH5c is overexpressed and associated with a poor prognosis in pancreatic cancer. We identified a small-molecule UbcH5c inhibitor, termed DHPO, which directly bound to UbcH5c protein. DHPO inhibited cell viability and colony formation, induced apoptosis, and suppressed migration and invasion of pancreatic cancer cells in vitro. The compound inhibited UbcH5c-mediated IκBα degradation and NF-κB activation, which is critical for its anticancer activity. Furthermore, DHPO suppressed the tumor growth and metastasis in two orthotopic pancreatic tumor mouse models. These results indicated that inhibiting UbcH5c is a novel and effective strategy for treating pancreatic cancer and DHPO represents a new class of UbcH5c inhibitor and may be further developed as an anti-pancreatic cancer therapeutic agent.
Sections du résumé
BACKGROUND
Pancreatic cancer is one of the most lethal cancers worldwide. The IAPs function as E3 ubiquitin ligases and contribute to pancreatic cancer initiation, progression, and metastasis. Although IAP-targeted therapies have been developed and shown anticancer efficacy in preclinical settings, none of them has been approved yet.
METHODS
Transcriptome data from public datasets were used to analyze the correlation of IAPs and E2s, and the biological function of E2 UbcH5c in pancreatic cancer. A structure-based virtual screen was used to identify UbcH5c inhibitor, and surface plasmon resonance analysis and cellular thermal shift assays were employed to evaluate the binding affinity. The anticancer activities were demonstrated through in vitro and in vivo assays, while the related mechanisms were explored through transcriptomic and proteomic analyses and confirmed by western blot, immunofluorescence, and qRT-PCR.
RESULTS
UbcH5c is positively correlated with the expression of IAPs in pancreatic cancer. We further found that UbcH5c is overexpressed and associated with a poor prognosis in pancreatic cancer. We identified a small-molecule UbcH5c inhibitor, termed DHPO, which directly bound to UbcH5c protein. DHPO inhibited cell viability and colony formation, induced apoptosis, and suppressed migration and invasion of pancreatic cancer cells in vitro. The compound inhibited UbcH5c-mediated IκBα degradation and NF-κB activation, which is critical for its anticancer activity. Furthermore, DHPO suppressed the tumor growth and metastasis in two orthotopic pancreatic tumor mouse models.
CONCLUSIONS
These results indicated that inhibiting UbcH5c is a novel and effective strategy for treating pancreatic cancer and DHPO represents a new class of UbcH5c inhibitor and may be further developed as an anti-pancreatic cancer therapeutic agent.
Identifiants
pubmed: 35272681
doi: 10.1186/s12943-022-01538-4
pii: 10.1186/s12943-022-01538-4
pmc: PMC8908661
doi:
Substances chimiques
NF-kappa B
0
Ubiquitin-Conjugating Enzymes
EC 2.3.2.23
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
70Informations de copyright
© 2022. The Author(s).
Références
Antioxid Redox Signal. 2017 Oct 10;27(11):754-768
pubmed: 28186440
J Med Chem. 2020 Aug 13;63(15):7957-7985
pubmed: 32142281
Drug Discov Today. 2020 Sep 16;:
pubmed: 32947046
Oncol Lett. 2020 Aug;20(2):1462-1468
pubmed: 32724389
J Nat Prod. 2010 Jun 25;73(6):1117-20
pubmed: 20515062
FEBS J. 2019 Dec;286(24):4889-4909
pubmed: 31715067
Lancet. 2020 Jun 27;395(10242):2008-2020
pubmed: 32593337
Trends Cell Biol. 2021 Mar;31(3):166-178
pubmed: 33422358
Chem Biol. 2014 Oct 23;21(10):1341-1350
pubmed: 25200604
Nat Rev Clin Oncol. 2019 Jan;16(1):11-26
pubmed: 30341417
Nucleic Acids Res. 2020 Jul 2;48(W1):W463-W471
pubmed: 32449936
Front Cell Dev Biol. 2020 Apr 02;8:233
pubmed: 32300595
Oncotarget. 2015 Feb 20;6(5):2623-40
pubmed: 25739118
Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220
pubmed: 30718832
Theranostics. 2020 Apr 27;10(13):5790-5801
pubmed: 32483419
Signal Transduct Target Ther. 2020 Feb 29;5(1):11
pubmed: 32296023
Nat Commun. 2014 Oct 01;5:5086
pubmed: 25271708
Pharmacol Ther. 2020 Oct;214:107610
pubmed: 32585232
Lancet Oncol. 2020 Mar;21(3):e135-e145
pubmed: 32135117
Int J Mol Sci. 2021 Mar 26;22(7):
pubmed: 33810518
J Med Chem. 2017 Aug 24;60(16):6828-6852
pubmed: 28696694
Cancer Lett. 2019 Sep 10;459:156-167
pubmed: 31181320
Cancer Lett. 2020 Oct 1;489:66-78
pubmed: 32544514
Front Pharmacol. 2020 Apr 08;11:457
pubmed: 32322210
Cancer Res. 2018 Oct 1;78(19):5656-5667
pubmed: 30217928
PLoS One. 2013;8(3):e56954
pubmed: 23469177
J Cell Physiol. 2021 Oct;236(10):6868-6883
pubmed: 33629745
Tumour Biol. 2013 Jun;34(3):1473-7
pubmed: 23355337
Onco Targets Ther. 2019 Nov 15;12:9767-9781
pubmed: 31814735
Pharmacol Ther. 2020 Sep;213:107579
pubmed: 32442437
Nat Rev Gastroenterol Hepatol. 2020 Aug;17(8):487-505
pubmed: 32393771
J Cancer. 2019 Feb 26;10(6):1528-1537
pubmed: 31031863
J Biol Chem. 2014 Feb 21;289(8):5097-108
pubmed: 24403071
Trends Cancer. 2020 Aug;6(8):677-687
pubmed: 32409139
Gastroenterology. 2014 Oct;147(4):893-902.e2
pubmed: 25016295
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Lett. 2021 Apr 28;504:125-136
pubmed: 33607208
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Int J Mol Sci. 2020 Sep 01;21(17):
pubmed: 32882786
Cell Res. 2017 May;27(5):657-674
pubmed: 28322253
Nat Rev Clin Oncol. 2020 Sep;17(9):527-540
pubmed: 32398706
Nat Rev Immunol. 2018 May;18(5):309-324
pubmed: 29379212
Med Res Rev. 2020 May;40(3):856-880
pubmed: 31587329
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348
pubmed: 29717230
Nat Struct Mol Biol. 2014 Apr;21(4):301-7
pubmed: 24699078
Eur J Med Chem. 2013 Oct;68:473-481
pubmed: 24044895
J Med Chem. 2019 Jun 27;62(12):5750-5772
pubmed: 30676015
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Mol Clin Oncol. 2013 Mar;1(2):305-308
pubmed: 24649165
J Biol Chem. 2013 Feb 1;288(5):2941-50
pubmed: 23233665